Creation of a rectal cancer registry in Italy by the Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network [version 1; peer review: 2 approved]

• Main Authors: Giulio M. Mari, Pietro Achilli, Dario Maggioni, Jacopo Crippa, Andrea T.M. Costanzi, Mauro A. Scotti, Vittorio Giardini, Mattia Garancini, Eugenio Cocozza, Giacomo Borroni, Ilaria Benzoni, Mario Martinotti, Luigi Totaro, Matteo Origi, Michele Mazzola, Giovanni Ferrari, Antonio Ziccarelli, Roberto Petri, Vincenzo Bagnardi, Giacomo Pugliese, Antonello Forgione, Raffaele Pugliese, AIMS Academy Clinical Research Network
• Format: Article
• Language: English
• Published: F1000 Research Ltd 2019-10-01
• Series: F1000Research
• Online Access: https://f1000research.com/articles/8-1736/v1

Background: The management of rectal cancer is multimodal and involves a multidisciplinary team of cancer specialists with expertise in medical oncology, surgical oncology, radiation oncology and radiology. It is crucial for highly specialized centers to collaborate via networks that aim to maintain uniformity in every aspect of treatment and rigorously gather patients’ data, from the first clinical evaluation to the last follow-up visit. The Advanced International Mini-Invasive Surgery (AIMS) academy clinical research network aims to create a rectal cancer registry. This will prospectively collect the data of patients operated on for non-metastatic rectal cancer in high volume colorectal surgical units through a well design pre-fashioned database for non-metastatic rectal cancer, in order to take all multidisciplinary aspects into consideration. Methods/Design: The protocol describes a multicenter prospective observational cohort study, investigating demographics, frailty, cancer-related features, surgical and radiological parameters, and oncological outcomes among patients with non-metastatic rectal cancer who are candidates for surgery with curative intent. Patients enrolled in the present registry will be followed up for 5 years after surgery. Discussion: Standardization and centralization of data collection for neoplastic diseases is a virtuous process for patient care. The creation of a register will allow the control of the quality of treatments provided and permit prospective and retrospective studies to be carried out on complete and reliable high quality data. Establishing data collection in a prospective and systematic fashion is the only possibility to preserve the enormous resource that each patient represents.